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QUALITY OF LIFE AND PSYCHOSOCIAL FUNCTIONING AFTER ALLOGE-
NEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)
FROM MATCHED SIBLING COMPARED TO UNRELATED DONORS
Hamilton, B.K.1, Lazaryan, A.1, McLellan, L.1, Rybicki, L.2, Foster, L.3,
Cooper, M.1, Dabney, J.1, Tench, S.1, Sobecks, R.1, Duong, H.1,
Kalaycio, M.1, Bolwell, B.J.1, Copelan, E.A.1 1Cleveland Clinic Taussig
Cancer Institute, Cleveland, OH; 2Cleveland Clinic Taussig Cancer Insti-
tute, Cleveland, OH; 3Cleveland State University, Cleveland, OH
Previous studies have shown similar survival outcomes between
matched unrelated donor (URD) and matched sibling donor
(MSD) transplants. Little data evaluates how this impacts quality
of life (QOL) and psychosocial functioning (PF). The purpose of
this study was to evaluate and compare QOL between pts undergo-
ing URD vs MSD allo-HSCT.
We prospectively collected QOL and PF assessments in 239 pts
whounderwent allo-HSCT from2004-2010 at our single institution.
Pts completed three validated psychometric tools—Functional As-
sessment of Cancer Therapy-Bone Marrow Transplantation
(FACT-BMT), Coping Inventory (Brief COPE), and Profile of
Mood States Short Form (POMS)—at five time points; (baseline,
post-transplant, day 100, 180 and 365). Repeated measures analysis
of variance (RMANOVA) and linear mixed model analysis was used
to compare QOL scores by donor type and time. Secondary end-
points included overall survival (OS), relapse-free survival (RFS),
graft-versus-host-disease (GVHD), and relapse.Outcomeswere esti-
mated using Kaplan-Meier and cumulative incidence methods.
Of 239 pts identified, 47 were excluded due to lack of baseline psy-
chometric measurements. Of the remaining 192 pts, 108 received
HSCT fromURD and 84 fromMSD. There were no significant dif-
ferences in age, race, gender, co-morbidity index, diagnosis, type of
transplant (myeloablative vs reduced intensity), and CD34+ dose.
There was a difference between time to transplant (7.1 mos for
URD vs 5.2 for MSD; p 5 0.014); preparative regimen (p 5
0.003); and GVHD prophylaxis (p\0.001). Differences were also
seen in days until neutrophil (11 vs 16) and platelet (17 vs 23) recov-
ery, as well as length of hospital stay (27 vs 35), (p\0.001); withMSD
having shorter times as compared with URD. There were no signif-
icant differences between baselineQOL and PF between the groups.
We saw trends indicating a general decrease in QOL post-discharge
with improvement by day 365; but no differences noted between
MSD or URD groups. URD transplants had higher Social Well Be-
ing scores at day 365 (p5 0.025) than MSD, but in no other param-
eters, and is of unclear significance. With a mean follow up of 33-40
months, therewere 43 (40%)URDand 31 (37%)MSD transplant pts
alive. There were no significant differences between URD andMSD
transplant in regards to GVHD (p 5 0.19), relapse (p 5 0.09), OS
(p 5 0.96), or RFS (p 5 0.80). This study demonstrates that this
also correlates with similar QOL and PF between the two groups.205
EARLY READMISSION RATES AFTER AUTOLOGOUS AND ALLOGENEIC
HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION (HPCT)
Hamilton, B.K.1, Serafino, S.1, Kalaycio, M.1, Andresen, S.1,
Pohlman, B.1, Dean, R.1, Hill, B.T.1, Hanna, R.2, Duong, H.1,
Sweetenham, J.W.1, Sweetenham, J.W.1, Copelan, E.A.1,
Bolwell, B.J.1, Sobecks, R.1 1Cleveland Clinic Taussig Cancer Institute,
Cleveland, OH; 2Cleveland Clinic, Cleveland, OH
Thirty-day readmissions are being targeted as a way to improve
cost and quality of medical care. Patients who undergo HPCT often
require extensive medical care and frequent hospitalization. It has
been demonstrated that readmissions within 30d of a transplant hos-
pitalization are associated with increased mortality. In this study, we
retrospectively reviewed all 30d readmissions at our institution in
2010 after an auto or allo-HPCT.
Ninety-nine auto-HPCT were done in 2010, with 11 readmis-
sions. Ten pts (10%) were readmitted after their initial hospitaliza-
tion within a median time of 4d (range 1-8). Diagnoses included 2
HL, 3 NHL, and 5 MM. One pt was readmitted a second time, 7d
after previous hospitalization. The most common reason for read-
mission was fever/infection (63%). Other reasons included gastroin-testinal symptoms (33%) and thromboembolism (11%). There was
one death secondary to failure to thrive and subsequent septicemia,
occurring 5d after readmission.
There were a total of 62 allo-HPCT done in 2010. Eighteen pts
(29%) were readmitted within 30d of their initial transplant hospital-
ization. Median time to readmission was 9.5d (range 2-30). The ma-
jority of these admissions (n5 14, 78%) were within the first 15d of
hospital discharge.Diagnosis included7AML, 4ALL, 4MDS,1MF,
1NHL, and 1AA.Donor type included 4UCB, 3MUD, and 5MSD.
There was no correlation with CIBMTR co-morbidity index scores,
which ranged from 0-6. Six (33%) pts were subsequently readmitted
at least one more time (range, 2-4 times) within 30d from previous
hospitalization. Nine (50%) of the 30d readmissions after allo-
HPCT were due to fever/infection, followed by 5 (28%) for
GVHD-related symptoms, and 4 (22%) for symptom management
(chest pain, nausea/vomiting, diarrhea). There were 3 deaths in this
early readmission group, all related to infection orGVHDcomplica-
tions. Median time to death after readmission was 31d (range 27-96).
We previously reported readmissions after HPCT portend poor
survival (Mohan et al 2010; Bejanyan et al 2010). The current anal-
ysis revealed that these readmissions tended to occur early, within
a median time of 4d (for auto) and 10d (for allo). At our institution,
we have implemented a review committee that evaluates all 30d read-
missions. In addition, we instituted a stringent follow-up policy in
which pts are seen within 3d of discharge. Further study of early re-
admissions may decrease their frequency and improve quality of
medical care.206
EVALUATION OF FACTORS ASSOCIATED WITH DAYS OUT OF THE
HOSPITAL FOR PATIENTS UNDERGOING UMBILICAL CORD BLOOD
TRANSPLANTATION
Riffkin, I.1, Filippo, M.1, Katherine, G.A.1, Colleen, D.1,2 1Fred Hutch-
inson Cancer Research Center, Seattle, WA; 2University of Washington
School of Medicine, Seattle, WA
Background:Umbilical cord blood transplantation (UCBT) is a fea-
sible option to treat hematologic malignancies in patients lacking
a suitably matched conventional donor. However, the median time
to hematopoietic recovery after UCBT is prolonged compared to
conventional donor transplants, and as a result UCBT patients
may spend more time hospitalized for complications in the first
100 days post transplant. We evaluated risk factors associated with
prolonged hospitalization in patients undergoing UCBT.
Methods:We performed a retrospective analysis of patients receiv-
ing UCBT at the University of Washington (UW) and the Seattle
Childrens Hospital (SCH), between January 2006 and April 2011.
Fifty-two patients (62%) were conditioned with cyclophosphamide
(CY) 60 mg/kg, fludarabine (FLU) 75 mg/m2 and total body irradi-
ation (TBI) 1320 cGy; 19 (23%) with Treosulfan 14 mg/m2, FLU
200 mg/m2 and TBI 200 cGy; and 13 (15%) with CY 50 mg/kg,
FLU 200 mg/m2 and either TBI 200 or 300 cGY. GVHD prophy-
laxis consisted of cyclosporine andMMF. The primary outcome was
the number of days alive and out of the hospital within the first 100
days post-transplantation. Linear regression models were used to es-
timate differences in the primary outcome between patient groups.
Variables considered included age, sex, race, institution, disease
risk, CMV serostatus, comorbidity score, conditioning regimen,
TBI dose and number of donor units.
Results:A total of 84 patients were included in the analysis; 57 (68%)
were adult and27 (32%)pediatric.Nine (11%)patients received a sin-
gle graft whereas 71 (84%) and 4 (5%) received double and triple
grafts, respectively. Fifteen (18%) patients received ex-vivo expanded
CD34+ units. Sixty-nine (82%) patients had leukemia, 7 (8%) had
a lymphoproliferative disorder, and 8 (10%) had MDS/myeloprolif-
erative disease.Thirteen (15%)patients died in thefirst 100days.The
median number of days alive and out of the hospital was 54 (range
0-92). In both univariate and multivariable analyses, only transplan-
tation at SCH, non-Caucasian race and high risk disease were signif-
icantly associated with fewer days alive and out of hospital [Table 1].
Conclusion: UCBT recipients spent over one-half of the first 100
days after transplant hospitalized; age, race and disease risk were
the most important predictors. Future directions for research
S280 Poster Session Iinclude associating these findings with an accurate cost analysis of
UCBT.
Table 1. Unadjusted Associations of Transplant Characteris-
tics with Days Alive and Out of Hospital
Median Coefficient
N (IQR*) (95% CI) p-value†Age 0.16
1-19 26 43 (19-57) 0 (reference)
20-34 20 52 (23-75) 9.1 (-7.7, 25.8)
35-49 20 67 (36 – 77) 15.2 (-1.5, 31.9)
50-73 18 72 (15 -86) 18.2 (0.9, 35.4)
Institution 0.03
UW Medical Center 57 66 (28 – 79) 0
Seattle Children’s
Hospital27 40 (19 – 57) -14.9 (-28.1, -1.7)Sex 0.21
Female 42 61 (28 – 76) 0
Male 42 53 (12 – 73) -8.1 (-20.6, 4.4
Race 0.002
Caucasian 49 66 (38 – 77) 0
Non-Caucasian 35 38 (14 – 60) -19.5 (-31.6, -7.4)
Disease-Risk 0.02
Standard 74 59 (29 – 76) 0
High 10 15 (0 – 57) -22.7 (-41.6, -3.8)
CMV seropositivity 0.05
Neg 31 66 (40 – 77) 0
Pos 53 46 (14 – 73) -12.9 (-25.7, -0.1)
Comorbidity score
(in adults)0.590, 1 14 50 (34 – 64) 0
2 19 73 (38 – 79) 11.8 (-8.8, 32.4)
3 14 50 (27 – 66) -1.1 (-23.3, 21.0)
4 – 8 15 66 (15 – 83) 5.3 (-16.5, 27.0)
Conditioning
regimen0.34CY / Flu / TBI 65 59 (20 – 76) 0
Treo / Flu / TBI 19 46 (14 – 68) -7.3 (-22.4, 7.7)
TBI dose (cGy) 0.46
200 – 300 32 59 (21 – 81) 0
1320 52 54 (20 – 71) -4.9 (-17.9, 8.0)
Number of donors 0.39
1 9 38 (14 – 54) -10.9 (-31.1, 9.4)
2 71 59 (27 – 77) 0
3 4 29 (14 – 58) -14.8 (-44.2, 14.7)*IQR 5 inter-quartile range, 25th to 75th percentiles of distribution
†Test for homogeneity across factor levels207
BONE MINERAL DENSITY CHANGES IN PATIENTS WITH b-THALASSEMIA
MAJOR AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
Hamidieh, A.A.1,Mohajeri-Tehrani,M.R.2,Mirboluk,M.1, Hamdi, A.1,
Behfar, M.1, Jalili, M.1, Shamshiri, A.R.1, Ghavamzadeh, A.1 1Tehran
University of Medical Sciences, Tehran, Islamic Republic of Iran; 2Tehran
University of Medical Sciences, Tehran, Islamic Republic of Iran
Introduction: Low bone mineral density (BMD) is an important
multifactorial cause of morbidity in patients with b-thalassemia.
With recent therapeutic advances such as hematopoietic stem cell
transplantation (HSCT), thalassemic patients can live longer but os-
teoporosis is now a major health concern.
Method: In this study, we evaluated the changes of bone density in
46 patients with b thalassemia major who were candidates for HSCT
before and after transplantation. The average age of patients was 13.4
years (range 3-29 years). Twenty four patients (52.2%) were male.
All patients underwent HSCT from HLA-identical related donors.
Nine patients (19.6%) co-transplanted with mesenchymal cells.
Dual-energy X-ray absorptiometry (DXA) was performed on lumbar
vertebrae and femoral neck in all patients before starting pre-
transplant regimens and repeated at one year after transplantation.
Results: Low BMD was found in 7 patients (15.2%) before trans-
plantation and in 18 patients (39.1%) one year after transplantation.BMD changes in femoral neck and lumbar area were significant at
one year after transplant (p\0.001) while no significant changes
were found in the whole femur (p 5 0.22). Female gender (p 5
0.005) and low body mass index (p 5 0.05) were correlated with
low BMD and defined as independent risk factors for low BMD at
one year after transplantation. There was no significant difference
inBMDchanges betweenpatientswith andwithout co-transplantation
of mesenchymal cells.
Conclusion:Due to decrease in BMDafterHSCT, it is suggested to
manage low BMD before transplantation. Longer follow-up will
help to better clarify the role of HSCT in BMD changes of thalasse-
mic patients; moreover, further studies are suggested to evaluate the
role of co-transplantation of HCT together with mesenchymal cells
on BMD improvement of thalassemic patients.208
MEDICATION ERRORS AMONG PEDIATRIC HEMATOPOIETIC STEM CELL
TRANSPLANT RECIPIENTS IN AN OUTPATIENT CLINIC
McDonald, L.R., Luke, J., Jude, V., Madden, R., Chan, K. Texas Trans-
plant Institute, Methodist Children’s Hospital, San Antonio, TX
As care of hematopoietic stem cell transplant (HSCT) patients is
increasingly provided in the ambulatory setting a significant amount
of responsibility is also switched to family members. The goal of this
project was to identify the incidence and source of medication errors
in a complex outpatient population and to develop system changes to
increase safety and reliability of home administration of medications.
Between 05/11 and 08/11, a prospective study was conducted on
pediatric HSCT recipients managed in a hospital-based outpatient
clinic. Patients within one year post-transplant or later if still on im-
munosuppressive therapy were included. Medication reconciliation
was performed by a clinic nurse every visit and verified by one of
two advanced nurse practitioners (ANP). The latter compared the
information with dictated clinic notes to confirm accuracy of medi-
cation administration. For variance the ANP determined the source
of error and clinical consequence, if any. The results were conferred
with the transplant physician for change of management.
Medications were classified as immunosuppressives (IS), anti-
infectives (AI) and others (OT). 300 visits (285 allogeneic HSCT-
and 15 autologous HSCT) occurred among 49 patients during the
4-month period. 19 medication errors were identified (6% inci-
dence) among 10 patients. 5 patients experienced multiple episodes
of error. All were administration errors. 18 errors (95%) occurred
at home and one (5%) in the clinic. 18 errors were found in alloge-
neic patients, 1 in an autologous patient. 7 errors (37%) involved
IS, 7 (37%) involved AI, and 5 (26%) fromOT.Themedian time be-
fore an error was detected was 2 (range 1-24) days. Themedian num-
ber of drugs taken by each patient was 6 (range 3-14). The nature of
the errors was wrong dose (too high 42%, too low 21%) and omis-
sion of a dose (7%). The source of the error was traced to miscom-
munication in 16 events (verbal 16%, written 68%), prescriber error
once (5%), and failure of caregiver to refill medication twice (11%).
No patient demonstrated significant clinical side-effects from medi-
cation errors. Many medications given post HSCT have a narrow
therapeutic window. Family members must take responsibility for
many skills quickly post HSCT. Standardized dosing strategies
and improved communication between the caregivers and healthcare
providers may decrease error rate and improve medication adher-
ence and safety of the care delivered.209
EFFECT OF BUSULFAN AND TOTAL BODY IRRADIATION ON DENTAL
DEVELOPMENT AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
IN CHILDHOOD
Dahllof, G.1, Wondimu, B.1, Garming-Legert, K.1, Remberger, M.2,
Ringden, O.2 1Karolinska Institutet, Huddinge, Sweden; 2Karolinska
University Hospital, Huddinge, Sweden
Children treated with hematopoietic stem cell transplantation
(HSCT) are at particular risk to develop disturbances in dental
